← Back to Search

Behavioural Intervention

Exercise Training for Heart Disease (EXCEED2 Trial)

N/A

Waitlist Available

Led By Jennifer Reed, PhD

Research Sponsored by Ottawa Heart Institute Research Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Patient has NYHA class III-IV heart failure symptoms, unstable angina, or established diagnosis of chronic obstructive pulmonary disease, severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy

Patient has uncontrolled arrhythmia

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline to 12 weeks and baseline to 26 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effects of two different types of virtual training on exercise capacity in women with coronary heart disease. Participants will be randomly assigned to either high-intensity interval training or moderate-to-vig

Who is the study for?

This trial is for women with coronary heart disease (CHD) who are interested in participating in a virtual exercise program. The study requires participants to train twice a week for 12 weeks, but specific inclusion and exclusion criteria details were not provided.

What is being tested?

The study is testing the effectiveness of two different virtual exercise programs: high-intensity interval training (HIIT) and moderate-to-vigorous intensity continuous training (MICT). Women will be randomly assigned to one of these programs to see which is better at improving exercise capacity and heart health.

What are the potential side effects?

While specific side effects are not listed, typical risks associated with physical exercise may include muscle soreness, fatigue, or injury. High-intensity workouts might increase these risks slightly compared to moderate exercises.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have severe heart or lung conditions.

Select...

I have an irregular heartbeat that is not under control.

Select...

I am unable to sign a consent form.

Select...

I cannot commit to follow-up visits at 12 and 26 weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline to 12 weeks and baseline to 26 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline to 12 weeks and baseline to 26 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to 12 weeks and baseline to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Exercise capacity

Secondary study objectives

Anxiety symptoms

Depressive symptoms

Disease-specific Quality of Life, global health, physical and emotional health

+10 more

Other study objectives

Feeling Scale

Participant Experience

Participant Feedback

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: standard care + moderate-intensity continuous exercise trainingExperimental Treatment1 Intervention

2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min

Group II: standard care + high-intensity interval trainingExperimental Treatment1 Intervention

2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exercise

2016

Completed Phase 1

~820

0 / 4Eligibility criteria met